期刊文献+

尼索地平治疗变异型心绞痛的临床疗效观察 被引量:2

Effect of nisoldipine on Prinzmetal’s variant angina pectoris
下载PDF
导出
摘要 目的观察尼索地平对变异型心绞痛的临床疗效。方法对变异型心绞痛65例随机分为治疗组(尼索地平)和对照组(地尔硫)分别给予尼索地平(早、晚各1次,每次5mg)和地尔硫(早、中、晚各1次,每次30mg)治疗,连服10d,观察两种药物对ST段抬高时间和临床缺血相关事件的影响。结果治疗组在减少ST段抬高时间和临床缺血相关事件发生率上均优于对照组,差异有显著性。结论尼索地平治疗变异型心绞痛临床疗效优于地尔硫。
出处 《中国心血管杂志》 2005年第4期304-305,共2页 Chinese Journal of Cardiovascular Medicine
  • 相关文献

参考文献3

二级参考文献16

  • 1陶萍.硝苯地平控释片的制剂特点[J].中华心血管病杂志,1994,22(5):326-327. 被引量:20
  • 2漆晓燕,张颖.硝苯吡啶治疗变异型心绞痛8例疗效分析[J].工企医刊,1995,8(2):63-64. 被引量:1
  • 3Schulte KL.24h anti-anginal and anti-ischaemic effects with once daily felodipine.A double-blind comparison with nifedipine, twice daily, and placebo in patients with stable exercise induced angina pectoris. Eur-Heart - J. 1995,16(2) : 171 ~ 6.
  • 4Watanabe K,Izumi T, Miyakita Y, et al. Efficcay of amlodipine besilate therapy for variant angina: evaluation by 24 - hour Holter monitoring. Cardiovase Drugs Ther. 1993,7(6) :923 - 928.
  • 5Sueda S, Saeki H, Otani T, et al.Limited efficacy of magnesium for the treatment of variant angina.J Cardiol. 1999,34(3) : 139 -147.
  • 6Nadazdin A, Davies GJ. Investigation of therapeutic mechanism of atenolol and diltiazedm in patients with variable-threshold angina.Am Heart J. 1994,127(2) :312 -317.
  • 7Motoyama T, Kawano H, Kugiyama K, et al. Vitamin E administration impairment of endothelium-dependent vasodilation in patients with coronary spastic angina.J Am Coll Cardiol.1998,32(6): 1672 - 1679.
  • 8Lablanche JM, Bautera C, McFadden EP, et al. Potassium channel activators in vasospastic angina. Eur Heart J. 1993,14 Suppl B:22 - 24.
  • 91,陈贵廷,等.最新国外疾病诊疗标准.第一版.学苑出版社,1991.125
  • 10吴鹏飞,徐振国,詹云龙.镁剂综合治疗变异性心绞痛的疗效观察[J].临床荟萃,1998,13(19):898-899. 被引量:12

共引文献8

同被引文献17

  • 1李华凌,翟光喜,焦玉举,王迪杰,宫清霞.尼索地平口腔黏附片的制备及影响因素考察[J].中国新药杂志,2007,16(10):783-787. 被引量:9
  • 2许景峰 赵维娟 张梅 等.31种药物的理化因素对透皮速率的影响[J].军队医药杂志,1997,7(2):40-40.
  • 3中国药典.二部[S].2010:凡例ⅩⅦ.
  • 4Mitrga KA,Varghese B,PorcM,et at.Anti-arrhythmic andhemodynamic effects of oxy nifedipine,oxy nimodipine,oxynitrendipine and oxy nisoldipine[J].Pharmacol Res,2012,66(4):300-308.
  • 5Rattanapak T,YoungK,Rades T,et al.Comparative studyof liposomes,transfersomes,ethosomes and cubosomes fortranscutaneous immunisation:characterisation and in vitroskin penetration[J].J Pharm Pharmacol,2012,64(11):1560-1569.
  • 6Celia C,Cilurzo F,Trapasso E,et al.Ethosomes and trans-fersomes containing linoleic acid:physicochemical and techno-logical features of topical drug delivery carriers for the poten-tial treatment of melasma disorders[J].Biomed Microdevices.2012,14(1):119-130.
  • 7Rakesh R,Anoop KR.Formulation and optimization of nano-sized ethosomes for enhanced transdermal delivery of cromolynsodium[J].J Pharm Bioallied Sci,2012,4(4):333-340.
  • 8Elsayed MM,Abdallah0Y,Naggar VF,etaL.Deformable li-posomes and ethosomes:mechanism of enhanced skin delivery[J].Int J Pharm,2006,322(1):60-66.
  • 9Panchagnula R,Salve PS,Thomasn S,etal.Transdermal de-livery of naloxone:effect of water,propylene glycol,ethanoland their binary combinations on permeation through rat skin[J].Int J Pharm,2001,219(1-2):95-105.
  • 10L pez-Pinto JM,Gonz Iez-Rodr guez ML,Rabasco AM.Effectof cholesterol and ethanol on dermal delivery from DPPC Iipo-somes[J].Int J Pharm,2005,298(1):1-12.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部